BeaconEquity.com - VIVUS Inc. (VVUS) Shares Surge 26% on Positive Test Results on Obesity Drug Qnexa
According to the Center for Disease Control and Prevention, adult obesity has increased 60 percent in the past 20 years, while obesity in children tripled in the past 30 years. Obesity-related diseases, such as diabetes and heart disease, kill more than 3
(EMAILWIRE.COM, May 28, 2008 ) BeaconEquity.com announces the publication of ‘VIVUS Inc. (VVUS) Shares Surge 26% on Positive Test Results on Obesity Drug Qnexa’
Investors can view all of the investment articles for free by visiting:
http://www.beaconequity.com/m - Click on News and Commentary
VIVUS Inc. (VVUS) Shares Surge 26% on Positive Test Results on Obesity Drug Qnexa
According to the Center for Disease Control and Prevention, adult obesity has increased 60 percent in the past 20 years, while obesity in children tripled in the past 30 years. Obesity-related diseases, such as diabetes and heart disease, kill more than 300,000 people each year. While Americans slowly drift toward healthier lifestyles, the demand for fast food and preservative-laden meals leaves pharmaceutical companies in a race to develop fat-fighting and life-saving solutions.
VIVUS Inc. engages in the development and commercialization of therapeutic products for underserved markets in the United States. The company recently announced its obesity drug Qnexa met its goal in treating cases of diabetes, sending shares of VIVUS up 26 percent to $7.20 Friday, touching a multi-year high of $7.32.
According to results, Qnexa led to a reduction in patients' blood glucose levels of 1.1 percent, compared with 0.6 percent in placebo patients. In addition, Qnexa-treated patients had a mean reduction in weight of 6.2 percent compared with 1.2 percent in placebo.
To read the entire article visit http://www.beaconequity.com/m – Click on News and Commentary
Join the fastest growing investor community at:
http://www.stockhideout.com
BeaconEquity.com’s Market News is one of the fastest growing small cap blogs in the investment community. Beacon is the authority on research in the small cap sector, and our analysts strive each day to find the stocks that are poised to be the biggest movers before the rest of the market is aware of them.
We encourage investors to subscribe to our FREE newsletter filled with daily trading ideas by visiting: http://www.beaconequity.com/m
BeaconEquity.com is one of the industry’s largest small cap research providers. Beacon strives to provide a balanced view of many promising small cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the publicly available information available on them. For more information on Beacon Research, please visit: http://www.beaconequity.com/m
Source: BeaconEquity.com
Beacon Equity Research
Jeff Bishop, (469)-252-3505
press@beaconequity.com
###
This press release was issued through GroupWeb EmailWire.Com. For more information on unlimited press release distribution, go to http://www.emailwire.com
Investors can view all of the investment articles for free by visiting:
http://www.beaconequity.com/m - Click on News and Commentary
VIVUS Inc. (VVUS) Shares Surge 26% on Positive Test Results on Obesity Drug Qnexa
According to the Center for Disease Control and Prevention, adult obesity has increased 60 percent in the past 20 years, while obesity in children tripled in the past 30 years. Obesity-related diseases, such as diabetes and heart disease, kill more than 300,000 people each year. While Americans slowly drift toward healthier lifestyles, the demand for fast food and preservative-laden meals leaves pharmaceutical companies in a race to develop fat-fighting and life-saving solutions.
VIVUS Inc. engages in the development and commercialization of therapeutic products for underserved markets in the United States. The company recently announced its obesity drug Qnexa met its goal in treating cases of diabetes, sending shares of VIVUS up 26 percent to $7.20 Friday, touching a multi-year high of $7.32.
According to results, Qnexa led to a reduction in patients' blood glucose levels of 1.1 percent, compared with 0.6 percent in placebo patients. In addition, Qnexa-treated patients had a mean reduction in weight of 6.2 percent compared with 1.2 percent in placebo.
To read the entire article visit http://www.beaconequity.com/m – Click on News and Commentary
Join the fastest growing investor community at:
http://www.stockhideout.com
BeaconEquity.com’s Market News is one of the fastest growing small cap blogs in the investment community. Beacon is the authority on research in the small cap sector, and our analysts strive each day to find the stocks that are poised to be the biggest movers before the rest of the market is aware of them.
We encourage investors to subscribe to our FREE newsletter filled with daily trading ideas by visiting: http://www.beaconequity.com/m
BeaconEquity.com is one of the industry’s largest small cap research providers. Beacon strives to provide a balanced view of many promising small cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the publicly available information available on them. For more information on Beacon Research, please visit: http://www.beaconequity.com/m
Source: BeaconEquity.com
Beacon Equity Research
Jeff Bishop, (469)-252-3505
press@beaconequity.com
###
This press release was issued through GroupWeb EmailWire.Com. For more information on unlimited press release distribution, go to http://www.emailwire.com
Contact Information:
Beacon Equity Research
Jeff Bishop
Tel: (469)-252-3505
Email us
This is a press release. Press release distribution and press release services by EmailWire.Com: http://www.emailwire.com/us-press-release-distribution.php.
Beacon Equity Research
Jeff Bishop
Tel: (469)-252-3505
Email us
This is a press release. Press release distribution and press release services by EmailWire.Com: http://www.emailwire.com/us-press-release-distribution.php.
Press Release Keywords:
stock market, investing, investment ideas, market activity, small caps, micro caps, beacon equity research, vivus inc., vvus, Qnexa, blood glucose, Diabetes
stock market, investing, investment ideas, market activity, small caps, micro caps, beacon equity research, vivus inc., vvus, Qnexa, blood glucose, Diabetes
|
Private Equity, Angel Investing
Equity Alliance / Private Equity, Angel Investing, / IPO, Venture Capital & IR services / Equity Alliance International Equityallianceir.com Penny Stocks to Watch Sign up for hot penny stock picks Gains of 500%+ possible! Premiumstockpicks.com/landing/ Your text Ads & PR Text Ads plus unlimited press releases, One release featured/Day for only $575 per month. Read more on Text Ads & PR Your text Ads Here! Text Ads are only $289 per month. Ads are placed same day. More on Text Ads Advertising |